Paratek Pharmaceuticals, Inc. Prices $140 Million of Convertible Senior Subordinated Notes due 2024

BOSTON, April 19, 2018 (GLOBE NEWSWIRE) — Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon tetracycline chemistry, today announced the pricing of $140 million aggregate principal amount of convertible senior subordinated notes that will mature on May 1, 2024, of which $5 million aggregate principal amount is being issued directly by Paratek to Paratek’s financial advisor in the transaction. The notes are being offered and sold only to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. Paratek has also granted the initial purchasers of …


Leave a Reply

Your email address will not be published.